Immunoglobulin‐like transcript 5 polarizes M2 ‐like tumor‐associated macrophages for immunosuppression in non‐small cell lung cancer
International Journal of Cancer · 2025
DOI: 10.1002/ijc.35360 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Huijun Xu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Jinan Central Hospital, Shandong University, Jinan, Shandong, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Tumor-Associated Macrophages, Receptors, Immunologic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the Jinan Science and Technology Innovation Program of Clinical Medicine, Health Commission of Anhui Province Scientific Research Project, National Natural Science Foundation of China.
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) have shifted the treatment paradigm of non‐small cell lung cancer (NSCLC) over the last decade. Despite notable therapeutic advancements in responders, the response rate remains limited owing to the immunosuppressive tumor microenvironment (TME). Therefore, to improve the efficacy of ICIs, it is essential to explore alternative targets or signals that mediate immunosuppression. Immunoglobulin‐like transcript (ILT) 5 is a negative regulator of immune activation in myeloid cells. However, the expression and function of ILT5 in NSCLC remain unknown. Here, we found that ILT5 was highly expressed in tumor‐associated macrophages (TAMs) of NSCLC tissues and predicted poor patient survival. Functionally, ILT5 induces the M2‐like polarization of TAMs, which subsequently decreases the density of T cells, and increases FOXP3 + T cell accumulation, leading to an immunosuppressive TME. The combination of ILT5 expression with M2‐like TAM density is a more reliable biomarker of patient survival than ILT5 expression alone. ILT5 knockout mitigates the reprogramming of TAM and T cell subsets toward immunosuppressive phenotypes and inhibits tumor growth in vivo. These findings highlight that ILT5 is a potential immunotherapeutic target and a promising prognostic biomarker for NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jinan Central Hospital, Shandong University, Jinan, Shandong, China.
- Department of Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
- Department of Thoracic Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
- Phase I Clinical Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
- Department of Oncology, The Fourth People's Hospital of Zibo, Zibo, Shandong, China.
- Department of Oncology, Central Hospital affiliated to Shandong First Medical University, Jinan, Shandong, China.
ORCID-Profile: Yifu He, Yuping Sun, Aiqin Gao
Förderung
- the Jinan Science and Technology Innovation Program of Clinical Medicine
- Health Commission of Anhui Province Scientific Research Project
- National Natural Science Foundation of China
- Shandong Provincial Natural Science Foundation
- Wu Jieping Medical Foundation
- Key R&D Program of Shandong Province
- Beijing Science and Technology Innovation Medical Development Foun-dation
- Chinese Society of Clinical Oncology-Gilead Cancer Research Foundation
Zitieren
APA
Xu, H., Fu, X., Wang, S., Ge, Y., Zhang, L., Li, J., Zhang, F., Yang, Y., He, Y., Sun, Y., & Gao, A. (2025). Immunoglobulin‐like transcript 5 polarizes M2 ‐like tumor‐associated macrophages for immunosuppression in non‐small cell lung cancer. International Journal of Cancer. https://doi.org/10.1002/ijc.35360
Vancouver
Xu H, Fu X, Wang S, Ge Y, Zhang L, Li J, et al. Immunoglobulin‐like transcript 5 polarizes M2 ‐like tumor‐associated macrophages for immunosuppression in non‐small cell lung cancer. International Journal of Cancer. 2025. doi:10.1002/ijc.35360
BibTeX
@article{Xu2025,
author = {Xu, Huijun and Fu, Xuebing and Wang, Shuyun and Ge, Yihui and Zhang, Lu and Li, Juan and Zhang, Fang and Yang, Yang and He, Yifu and Sun, Yuping and Gao, Aiqin},
title = {Immunoglobulin‐like transcript 5 polarizes M2 ‐like tumor‐associated macrophages for immunosuppression in non‐small cell lung cancer},
journal = {International Journal of Cancer},
year = {2025},
doi = {10.1002/ijc.35360}
}
EUVIMED